DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a
leading global contract research organization (CRO), today announced the launch
of its artificial intelligence (AI) Innovation Studio, signaling a strategic
investment in reshaping the execution of clinical trials today and into the
future.
The studio will develop and deploy AI and machine learning (ML) technologies to
drive speed, agility, quality and enhanced patient safety in the clinical
research process by equipping and empowering people to focus on the critical
human element of clinical trials.
"Patients around the world are waiting for novel, life-changing treatments. With
AI, we now have the power-and the obligation-to help deliver solutions to them
faster," said Fortrea's Chief Information Officer Alejandro Martinez Galindo.
"Fortrea's AI Innovation Studio will enable enhanced technological capabilities
that will allow AI-enabled systems to perform cutting-edge processes-such as
trial simulations, predictive analytics and pattern recognition-as well as
repetitive, administrative, 'machine-friendly tasks'. This frees up people to
contribute human creativity and connection to the clinical trial of tomorrow and
focus on what counts: the patient."
Fortrea's AI Innovation Studio aims to:

  * Partner across Fortrea and with our customers to provide technology
    solutions for bespoke site and sponsor innovation strategies;

* Develop net new, greenfield technology innovations that holistically improve the delivery of clinical trials for sponsors, sites, patients and our teams;

    and
  * Support existing infrastructure and operations with enhanced technology to
    enable new, improved ways of working and create best-in-class user
    experiences.

Technologies under development in the studio include smartphone-enabled data
collection; specialized large language models for text comprehension and
generation; symbolic AI with real-valued logic (i.e., building decision logic
using real-world scenarios and data); mixed reality and augmented intelligence;
advanced data mining and predictive analytics; and digital twinning.
Strategic application of these technologies is expected to result in meaningful
advancements in patient recruitment and retention, protocol
creation/optimization, risk-based quality monitoring and overall delivery speed
and quality. These technologies can also deliver an improved patient experience
and greater productivity for Fortrea customers, sites and employees.
Developments from the AI Innovation Studio will be critical to Fortrea's
clinical technology platform, which is being designed to integrate clinical
trial technology into a consumer-grade, location-agnostic, omni-channel,
persona-based experience accessible thorough a single screen.
"Fortrea is focused on a future vision of the CRO industry, allowing us to build
TO the future rather than FROM the past," said Brian Dolan, Vice President of
Artificial Intelligence & Machine Learning. "We are exercising great care and
consideration to the responsible and ethical development and deployment of AI,
prioritizing doing the right thing for the right reasons and protecting patient
safety and privacy, and the intellectual property of our customers."
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development
solutions to the life sciences industry. We partner with emerging and large
biopharmaceutical, biotechnology, medical device and diagnostic companies to
drive healthcare innovation that accelerates life-changing therapies to
patients. Fortrea provides phase I-IV clinical trial management, clinical
pharmacology and consulting services. Fortrea's solutions leverage three decades
of experience spanning more than 20 therapeutic areas, a passion for scientific
rigor, exceptional insights and a strong investigator site network. Our talented
and diverse team working in more than 90 countries is scaled to deliver focused
and agile solutions to customers globally. Learn more about how Fortrea is
becoming a transformative force from pipeline to patient at Fortrea.com
(http://www.fortrea.com)and follow us on LinkedIn
(https://www.linkedin.com/company/fortrea/)and X
(https://x.com/Fortrea) (formerly Twitter).
Fortrea Contacts:
Hima Inguva (Investors) - 877-495-0816, hima.inguva@fortrea.com
(https://www.globenewswire.com/Tracker?data=_GGmkKY2IEErLJf-86-
IG3e0VZb70F62LhvT2GnC-
nlO59prgBz8QDZrdZugpDe3Z640Je3pY53jV_tvHu62qNuAUcIlxHCyDTZWbihVCgw=)
Jennifer Minx (Media) - 919-410-4195, media@fortrea.com
(https://www.globenewswire.com/Tracker?data=97caLJYhjY4t4eupQg1xSsyq9D0dfunBfYRi
dfoB0C-pENUJECFlDzP3TJ1h4Z-yVfjqRxNikGbrAEgeT962cN2BKLEysrx6no6FxGLIbcQ=)
Kate Dillon (Media) - 646-818-9115, kdillon@prosek.com
(https://www.globenewswire.com/Tracker?data=7WpjSg3v1ct2SBDA94Gxk-eh0Y2-L-
spU1fYfXdW3XVvxztzou_0sF9WxiQ7pxkaT5NhitQip5LKgVXt0isB9fHV5SGXE9Hpe-or03CXNS0=)
Â